Clinical Significance of CDKN2A Homozygous Deletion in Combination With Methylated MGMT Status for IDH-Wildtype Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Cancer Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Clinical Significance of CDKN2A Homozygous Deletion in Combination With Methylated MGMT Status for IDH-Wildtype Glioblastoma
Cancer Med 2021 Apr 10;[EPub Ahead of Print], Y Funakoshi, N Hata, K Takigawa, H Arita, D Kuga, R Hatae, Y Sangatsuda, Y Fujioka, A Sako, T Umehara, T Yoshitake, O Togao, A Hiwatashi, K Yoshimoto, T Iwaki, M MizoguchiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.